08 Dec 2025
16m
ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.